ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Structure Therapeutics Inc

Structure Therapeutics Inc (GPCR)

42.86
-0.05
(-0.12%)
Closed March 29 04:00PM
42.91
0.05
(0.12%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
42.86
Bid
39.77
Ask
44.44
Volume
380,260
41.905 Day's Range 44.37
0.00 52 Week Range 0.00
Market Cap
Previous Close
42.91
Open
43.43
Last Trade
1
@
43.3
Last Trade Time
Financial Volume
$ 16,353,412
VWAP
43.0059
Average Volume (3m)
-
Shares Outstanding
-
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Structure Therapeutics Inc

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impactin... Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. It is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Grand Cayman, Cym
Founded
1970
Structure Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GPCR. The last closing price for Structure Therapeutics was $42.91. Over the last year, Structure Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Structure Therapeutics currently has 0 shares outstanding.

GPCR Latest News

Form S-8 - Securities to be offered to employees in employee benefit plans

  As filed with the Securities and Exchange Commission on March 8, 2024   Registration No. 333-              UNITED...

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

0.815.5111019800095840000001888886FY001920000019200000128000001280000000003285700032857000216100021610000010527000139220000P2Y0.759812438false0001888886gpcr:ShareExchangeAgreementWithSubsidiariesMe...

Form 8-K - Current report

false 0001888886 True 0001888886 2024-03-08 2024-03-08 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001Per...

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in...

Form 8-K - Current report

false 0001888886 True 0001888886 2023-12-18 2023-12-18 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001Per...

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

GPCR Discussion

View Posts
TRADER99 TRADER99 6 months ago
$63 chart says possible $70 soon ,🤷🏻‍♂️ but that gap below little scary
👍️0
make it happen make it happen 6 months ago
Only in Phase 1b... and it's raising $300,000,000 at $12.49. Selling 24,000,000 shares at a 80+% discount...
👍️0
make it happen make it happen 6 months ago
Is only in phase 1 a very long way to go and lots of money burning
👍️0
make it happen make it happen 6 months ago
Profitability
Profit Margin 0.00%
Operating Margin 0.00%

$300,000,000 entering the market
24,000,000 shares @ $12.49 being sold
👍️0
make it happen make it happen 6 months ago
Let's see if $50 holds think will fall out no options. Reminds me of a small cap that fades...
👍️0
make it happen make it happen 6 months ago
It's raising $300,000,000 at $12.49. Selling 24,000,000 shares into the market.
👍️0
make it happen make it happen 6 months ago
Will be bank to $40 in a couple months
👍️0
MiamiGent MiamiGent 6 months ago
GPCR had a great day! Up 35% at the close- a lot higher intraday.
Here was the news:

Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
BENZINGA 8:55 AM ET Sep-29-2023

Structure Therapeutics Inc (NASDAQ:GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or obese individuals.

GSBR-1290 is an oral GLP-1 receptor agonist, similar to Novo Nordisk A/S's (NYSE:NVO) popular drug, Wegovy (semaglutide).

In the 28-day study, GSBR-1290 demonstrated significant weight loss supporting once-daily (QD) dosing.

GSBR-1290 demonstrated reductions in mean body weight ranging up to 4.9 kg compared to baseline and up to 4.9% placebo-adjusted.

The company is expected to report topline data from the type 2 diabetes cohort of the Phase 2a study in the latter half of Q4 of 2023.

Structure continues to plan to initiate two Phase 2b studies of GSBR-1290 in 2024. The type 2 diabetes study is expected to include approximately 500 individuals.

The company is also planning a separate formulation bridging PK study to support the planned transition from capsules to tablets, which is expected to be initiated in Q4 of 2023 and completed in Q2 of 2024. Pending supportive data from this bridging study, the tablet formulation would be used in future GSBR-1290 studies starting with the planned Phase 2b studies.

Concurrently, Structure Therapeutics announced a private placement of 21.6 million shares and 2.4 million newly designated non-voting shares at $12.49 per share, with gross proceeds of $300 million.

Net proceeds, along with existing cash, cash equivalents, and short-term investments, are expected to extend the cash runway through the end of 2026.

Price Action: GPCR shares are 68.1% at $62.98 during the premarket session on the last check Friday.
👍️0

Your Recent History

Delayed Upgrade Clock